Imaging Breast Cancer Bone Metastases: Current Status and Future Directions

Jennifer Glendenning, Gary Cook*

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

25 Citations (Scopus)

Abstract

The skeleton is commonly affected in the context of metastatic breast cancer and is a cause of significant morbidity in these individuals. Therapeutic options include systemic therapy, radiotherapy, and surgery given with the intent of preserving function and quality of life. As the spectrum of available therapies increases, key challenges comprise reliable diagnosis of bony metastatic disease and accurate evaluation of response that permits rapid therapeutic transition in those responding inadequately prior to development of significant skeletal morbidity. The Tc-99m-diphosphonate bone scan remains one of the most commonly requested investigations for skeletal evaluation in patients with breast cancer. However a time lag of 3-6 months for accurate response evaluation from the start of treatment limits its utility for response evaluation in routine clinical practice or as a progression end point in the research setting. Functional imaging strategies using more tumor-specific radiopharmaceuticals show promise as an effective means of imaging response at a clinically relevant time point and are the subject of this review. (C) 2013 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)317-323
Number of pages7
JournalSeminars in Nuclear Medicine
Volume43
Issue number4
DOIs
Publication statusPublished - Jul 2013

Keywords

  • POSITRON-EMISSION-TOMOGRAPHY
  • TREATMENT RESPONSE
  • F-18-FLUORIDE PET
  • TUMOR RESPONSE
  • PROGNOSTIC PARAMETERS
  • ESTROGEN-RECEPTORS
  • MONITOR TREATMENT
  • SYSTEMIC THERAPY
  • F-18-FDG PET/CT
  • PROSTATE-CANCER

Fingerprint

Dive into the research topics of 'Imaging Breast Cancer Bone Metastases: Current Status and Future Directions'. Together they form a unique fingerprint.

Cite this